Nureca Limited has informed the exchange regarding Book Closure date for Annual General Meeting.
NURECA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Nureca Limited's board meeting on May 29, 2026 approved audited FY26 standalone results showing revenue growth to Rs 1,472.10 million (up 28% from Rs 1,146.40 million in FY25). The company returned to profitability with PAT of Rs 2.97 million versus loss of Rs 6.68 million in FY25, though Q4 alone showed a loss of Rs 66.25 million due to Rs 83.37 million fair value loss on investments. Key leadership changes include CFO Mr. Naresh Gupta's resignation effective June 26 (citing better career opportunities) and promotion of Mr. Chander Kant to CFO from June 27. The board also approved Rs 100 crore capex for manufacturing expansion of medical devices and healthcare products at Derabassi, Punjab. The 10th AGM is scheduled for July 28, 2026 with book closure from July 22-28. Additionally, the company completed a share buyback at Rs 330 per share, reducing share capital to Rs 95.42 million.
The company achieved annual profitability despite weak Q4 performance; significant capex investment signals expansion but may pressure near-term cash flows. Leadership continuity is maintained through internal CFO promotion. Shareholders should note family-controlled board structure (Goyal family holds ~46% stake) and upcoming AGM approvals for director re-appointments.